自引率: 3.3%
被引量: 34162
通过率: 暂无数据
审稿周期: 1.57
版面费用: 暂无数据
国人发稿量: 174
投稿须知/期刊简介:
Cancer Letters is a journal providing rapid publication of brief articles in the broad area of cancer research. The journal places emphasis on the molecular and cell biology of cancer, oncogenes, carcinogenesis, radiation biology, molecular pathology, hormones and cancer, viral oncology, biology of cancer and metastasis, molecular cytogenetics, epidemiology; and experimental therapeutics. The primary criterion for publication is interest to a multidisciplinary audience. Papers should be brief but technically sound and substantiated by sufficient experimental detail. Clinical papers will be accepted if they contribute to the understanding of the basic mechanisms underlying disease. Papers published in Cancer Letters from January 2001 onwards will be divided into the following sections: Carcinogenesis & Cancer Prevention, Experimental Therapeutics, Epidemiology & Molecular Epidemiology, Molecular & Cell Biology, Tumour Biology. Authors are kindly requested to select the section where they wish their manuscript to appear when submitting their manuscript to the appropriate Editorial Office (please refer to the Guide for Authors for more information).
期刊描述简介:
Carcinogenesis is a multi-disciplinary journal designed to bring together all the varied aspects of research which will ultimately lead to the prevention of cancer in man. the journal will publish full papers and short communications which warrant prompt publication in the areas of viral physical and chemical carcinogenesis and mutagenesis; factors modifying these processes such as DNA repair genetics and nutrition; metabolism of carcinogens; the mechanism of action of carcinogens and promoting agents; epidemiological studies; and the formation detection identification and quantification of environmental carcinogens. Accelerated papers are of important and timely work chosen by the editors which merit a fast review process followed by rapid publication (6 weeks). The editors may from time to time invite commentaries or short reviews.
-
Corrigendum to "LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway" [Cancer Lett.374 (2016) 261-271].
被引量:- 发表:1970
-
Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways.
被引量:- 发表:1970
-
The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma.
被引量:- 发表:1970
-
Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives.
被引量:- 发表:1970
-
Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.
被引量:- 发表:1970